Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase 2 Study on Propranolol and Pembrolizumab in Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma - a Scandinavian Sarcoma Group Collaboration

NCT05961761 is registered in ClinicalTrials.gov with Niels Junker as lead sponsor.

NCT NCT05961761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05961761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase 2 Study on Propranolol and Pembrolizumab in Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma - a Scandinavian Sarcoma Group Collaboration
Lead sponsor
Niels Junker
Phase
Phase 2
Overall status
Recruiting
Start date
August 17, 2021
Completion date
December 31, 2028
Enrollment
80 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

angiosarcoma, soft tissue sarcoma adult, undifferentiated pleomorphic sarcoma